NexImmune, Inc.
NEXI
$0.00
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.08M | 2.01M | 2.54M | 3.99M | 2.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.73M | 2.76M | 1.58M | 10.00M | 7.78M |
| Operating Income | -2.73M | -2.76M | -1.58M | -10.00M | -7.78M |
| Income Before Tax | -2.33M | -3.08M | -5.36M | -9.85M | -7.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.33M | -3.08M | -5.36M | -9.85M | -7.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.33M | -3.08M | -5.36M | -9.85M | -7.57M |
| EBIT | -2.73M | -2.76M | -1.58M | -10.00M | -7.78M |
| EBITDA | -2.65M | -2.64M | -1.35M | -9.73M | -7.52M |
| EPS Basic | -1.69 | -2.46 | -5.04 | -9.40 | -7.25 |
| Normalized Basic EPS | -0.70 | -1.59 | -0.86 | -5.88 | -4.53 |
| EPS Diluted | -1.69 | -2.46 | -5.04 | -9.40 | -7.25 |
| Normalized Diluted EPS | -0.70 | -1.59 | -0.86 | -5.88 | -4.53 |
| Average Basic Shares Outstanding | 1.38M | 1.25M | 1.06M | 1.05M | 1.04M |
| Average Diluted Shares Outstanding | 1.38M | 1.25M | 1.06M | 1.05M | 1.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |